Shandong Wohua Pharmaceutical Co Ltd

The disclosure of A-share third-quarter reports has officially begun, and Wohua Pharmaceutical became the first company to disclose its 2026 third-quarter report. Wohua Pharmaceutical's third-quarter report shows that in the first three quarters of this year, the company achieved operating revenue of 589 million yuan, a year-on-year decrease of 5.73%; net profit attributable to shareholders of the listed company was 92.6545 million yuan, a year-on-year increase of 44.78%; net profit attributable to shareholders of the listed company after deducting non-recurring gains and losses was 90.6459 million yuan, a year-on-year increase of 47.94%; basic earnings per share were 0.16 yuan. Among them, net profit attributable to shareholders of the listed company in the third quarter was 25.0882 million yuan, a year-on-year increase of 29.87%; net profit after deducting non-recurring gains and losses was 24.6869 million yuan, a year-on-year increase of 33.19%. The company's profit growth benefited from a reduction in operating costs and selling expenses. During the reporting period, the National Health Commission issued the National Essential Medicines List 2026 Edition. Wohua Pharmaceutical's core product Xinkeshu Tablets continued to be included, and the core products Hedan Capsules and Hedan Tablets of its subsidiary Jiangxi Wohua Jishun Pharmaceutical Co., Ltd. were included in the list for the first time. Hedan Capsules and Hedan Tablets became the company's second exclusive pillar product to enter the essential medicines list after Xinkeshu Tablets. According to Wind statistics, several individual shareholders newly became among the top ten shareholders of Wohua Pharmaceutical.

The National Essential Medicines List, 2026 Edition, will officially take effect on September 1, containing 794 medicines with 116 new additions. Among the new lipid-regulating Chinese patent medicines are Hedan Tablets and Capsules, a product of Wohua Pharmaceutical. Wohua Pharmaceutical said Hedan Tablets and Capsules offer dual benefits in lipid regulation and weight reduction, meeting the clinical needs of overweight patients with dyslipidemia. Essential medicine status means assured hospital access and guaranteed usage volume. The National Health Commission has required public medical institutions at all levels to update their medicine lists within two months after implementation, giving priority to stocking essential medicines. Wohua Pharmaceutical said Hedan Tablets and Capsules are its second exclusive pillar product to enter the essential medicines list, after Xinkeshu Tablets, creating a dual essential medicine synergy for the company. It plans to promote Hedan's inclusion in weight-related guidelines through real-world studies from 2026 to 2028. In the first half of 2026, Wohua Pharmaceutical achieved operating revenue of 393 million yuan and net profit attributable to the parent company of 67.57 million yuan, up 51.23 percent year on year.

On the evening of August 11, several A-share listed companies released their 2026 mid-year dividend implementation plans or proposals. Among them, Action Education plans to distribute a cash dividend of 12 yuan per 10 shares, including tax, totaling 143 million yuan. Xinjiang Xintianran Gas plans to distribute 8 yuan per 10 shares, including tax, with an estimated total payout of 339 million yuan. Jangho Group plans to distribute 0.25 yuan per share, including tax, with an estimated total payout of 283 million yuan. Hikvision released its equity distribution implementation announcement, proposing a cash dividend of 5.50 yuan per 10 shares, including tax, to all shareholders, with a cumulative total dividend of 5.041 billion yuan. The record date is August 18. In addition, Yongjin Technology, Wohua Pharmaceutical, Hubei Yihua, Great Wall Sci-Tech, Dongbai Group, and Fushine Pharmaceutical also disclosed their dividend plans.

Wohua Pharmaceutical released its 2026 interim report, with net profit attributable to the parent company at 67.5663 million yuan, up 51.23% from the same period last year, marking two consecutive years of growth. The company's total operating revenue was 393 million yuan, down 7.53% year-on-year. Net cash inflow from operating activities was 81.3675 million yuan, an increase of 8.07% year-on-year. The company's latest asset-liability ratio is 26.32%, gross margin is 77.84%, ROE is 9.56%, and diluted earnings per share is 0.12 yuan.